BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nguyen-Tat M, Jäger J, Rey JW, Nagel M, Labenz C, Wörns MA, Galle PR, Marquardt JU. Terlipressin and albumin combination treatment in patients with hepatorenal syndrome type 2. United European Gastroenterol J 2019;7:529-37. [PMID: 31065370 DOI: 10.1177/2050640619825719] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Wong YJ, Kumar R, Chua YJJ, Ang TL. Long-term albumin infusion in decompensated cirrhosis: A review of current literature . World J Hepatol 2021; 13(4): 421-432 [PMID: 33959225 DOI: 10.4254/wjh.v13.i4.421] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Fida S, Khurshid SMS, Mansoor H. Frequency of Hepatorenal Syndrome Among Patients With Cirrhosis and Outcome After Treatment. Cureus 2020;12:e10016. [PMID: 32983712 DOI: 10.7759/cureus.10016] [Reference Citation Analysis]
3 Adachi T, Takaki A, Sato S, Tobita H, Kobashi H, Kinomura M, Nakatsuka A, Oyama A, Wada N, Sakata M, Takeuchi Y, Yasunaka T, Onishi H, Shiraha H, Okada H. High expression of a vascular stricture-related marker is predictive of an early response to tolvaptan, and a low fractional excretion of sodium is predictive of a poor long-term survival after tolvaptan administration for liver cirrhosis. Hepatol Res 2020;50:1347-54. [PMID: 32939957 DOI: 10.1111/hepr.13573] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Bejjani A, Zhang Y, Behrens A, Murray B, Shah N. Droxidopa in the Management of Hepatorenal Syndrome. J Pharm Pract 2022;:8971900221087974. [PMID: 35426352 DOI: 10.1177/08971900221087974] [Reference Citation Analysis]
5 Kulkarni AV, Arab JP, Premkumar M, Benítez C, Tirumalige Ravikumar S, Kumar P, Sharma M, Reddy DN, Simonetto DA, Rao PN. Terlipressin has stood the test of time: Clinical overview in 2020 and future perspectives. Liver Int 2020;40:2888-905. [DOI: 10.1111/liv.14703] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
6 Kumar R, Priyadarshi RN, Anand U. Chronic renal dysfunction in cirrhosis: A new frontier in hepatology. World J Gastroenterol 2021; 27(11): 990-1005 [PMID: 33776368 DOI: 10.3748/wjg.v27.i11.990] [Reference Citation Analysis]
7 Ali B, Salim A, Alam A, Zuberi BF, Ali Z, Azam Z, Kamani L, Farooqi JI, Salih M, Nawaz AA, Chaudhry AA, Hashmi ZY, Siddique M. HEP-Net opinion on the management of ascites and its complications in the setting of decompensated cirrhosis in the resource constrained environment of Pakistan. Pak J Med Sci 2020;36:1117-32. [PMID: 32704299 DOI: 10.12669/pjms.36.5.2407] [Reference Citation Analysis]